XtalPi Announces Collaboration With Lilly, Using AI + Robotics To Uncover First-In-Class Therapeutics
Portfolio Pulse from Happy Mohamed
XtalPi Inc. announced a $250 million AI drug discovery collaboration with Eli Lilly and Company. The partnership will leverage XtalPi's AI capabilities and robotics platform to design and deliver drug candidates for an undisclosed target.
May 30, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly partners with XtalPi in a $250 million AI drug discovery collaboration, leveraging AI and robotics to design and deliver drug candidates.
The collaboration with XtalPi, an industry leader in AI and robotics, could lead to the discovery of novel drug candidates for Eli Lilly. This partnership has the potential to accelerate drug development and reduce experimental costs, which could positively impact Eli Lilly's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100